Background {#Sec1}
==========

Osteoporosis is a disorder characterized by bone mass reduction and alterations in the micro-architecture of the bone tissue resulting in bone fragility and, consequently, an elevated risk of fractures \[[@CR1]\]. At present, osteoporosis is a public health problem in industrialized countries affecting about 30% of women and 8% of men older than 50 in Europe \[[@CR2]\]. Although it has typically been considered an adult disorder, it is becoming increasingly clear that osteoporosis might be rooted in childhood and adolescence \[[@CR3]\]. Bone matrix mineralization takes place during these stages of life, and therefore subjects reach peak bone mass at the end of this growth phase. If this peak is not optimal, it will facilitate the development of osteoporosis in adulthood \[[@CR3]\].

Furthermore, the incidence of childhood osteoporosis is increasing due to, among other factors, the increased survival rate of patients suffering from chronic diseases and the increased use of drugs that can damage bones \[[@CR4]\].

In its Official Positions published in 2013, the International Society for Clinical Densitometry considered two possible conditions regarding the diagnosis of childhood osteoporosis \[[@CR5]\]: Presence of one or more vertebral fractures (VF) in the absence of local disease or high-energy trauma.Z-score of bone mineral density (BMD) or bone mineral content (BMC) ≤ − 2 (adjusted for size in cases of children measuring below the 3rd percentile) and a history of clinically significant fractures; specifically: two or more long bone fractures occurring by age 10 years; orthree or more long bone fractures at any age up to age 19 years.

Moreover, their guidelines state that a Z-score higher than -2 does not preclude the possibility of bone fragility, especially in those patients suffering from disorders that favor secondary osteoporosis.

At present, in pediatrics there is growing interest in this pathology. However, recent changes made to the definition of childhood osteoporosis \[[@CR5], [@CR6]\], along with the lack of guidelines or national consensuses regarding its diagnosis and treatment, have resulted in a wide variability in the approaches used to treat this disease \[[@CR7]\].

For these reasons, the Working Group of Osteogenesis Imperfecta and Childhood Osteoporosis of the Spanish Society of Pediatric Rheumatology (SERPE, by its Spanish acronym) has sounded the need for developing guidelines to standardize clinical practice with regard to this pathology.

Methods {#Sec2}
=======

Design {#Sec3}
------

A qualitative synthesis of scientific evidence and consensus based on clinical experience and existing scientific evidence was used to formulate the study design.

Development stages {#Sec4}
------------------

Preparation began with the establishment of an expert panel comprised of 11 physicians, 6 pediatricians and 5 rheumatologists. All are members of the SERPE and have experience in the diagnosis and treatment of secondary osteoporosis in children.

Study coordination was undertaken by one of the physicians.

This panel of experts reached a consensus on the essential contents to include in the document, consisting of the following eight sections: When osteoporosis should be suspectedHow to prevent itLaboratory tests used in screeningImaging tests used in screeningTreatment: calcium and vitamin D supplementationTreatment: bisphosphonates (BPs)Follow-upGlucocorticoid-induced osteoporosis (GIOP)

One or two experts were appointed to be responsible for a literature review of each section, which was conducted with the assistance of a rheumatologist and an expert in methodology.

Following the revision, each of the experts responsible for the literature review provided recommendations regarding each section based on evidence, when that was available, or on their own experience.

Afterwards, the panelists held a meeting to discuss and draft the recommendations. The level of evidence was determined for each section using the Oxford Centre for Evidence-based Medicine (CEBM) system. For this purpose, both a rheumatologist and an expert in methodology provided guidance. A Delphi survey was conducted for those recommendations with an evidence level of IV or V. This survey was sent to all members of the SERPE. All recommendations that had a level of agreement higher or equal to 70% were included.

Results {#Sec5}
=======

A total of 51 recommendations, categorized into eight sections, were obtained (Table [1](#Tab1){ref-type="table"}). Twenty-four of them presented an evidence level 4 or 5, and therefore a Delphi survey was conducted. This was submitted electronically and received a response rate of 40%. All recommendations submitted to the Delphi round obtained a level of agreement of 70% or higher and were therefore accepted. Table 1Recommendations, levels of evidence, grade of recommendation according to the Oxford CEBM and level of agreement in Delphi round\*RecommendationLEGRLADRGeneral recommendations 1There is a need to monitor BMD in patients with chronic diseases, especially those of endocrinologic, nutritional, rheumatological, renal, metabolic, hematological, neurological and gastrointestinal origin. There is no universal consensus regarding when and how to carry out such an assessment for all the pathologies involved. Following the existing guidelines for each pathology is therefore recommended \[[@CR8]--[@CR22]\].4D95% 2Special attention must be paid to patients with chronic diseases who receive treatments that contribute to osteoporosis development; e.g., GCs, chemotherapy treatments or antiepileptic drugs \[[@CR17], [@CR19], [@CR20], [@CR23]--[@CR28]\].2bBLifestyle and dietary habits 3It is important to identify those children at risk for osteoporosis due to causes related to lifestyle, long-term immobilization or problems of anorexia or malnutrition \[[@CR19], [@CR29]--[@CR34]\].2aB 4Healthy dietary habits must be established by means of a balanced diet that meets specific calcium and vitamin D requirements for each age and allowing for adequate nutritional intake \[[@CR35], [@CR36]\].2aB 5Tobacco, caffeine and alcohol use must be avoided in children and adolescents \[[@CR35], [@CR37], [@CR38]\] \[[@CR39]--[@CR41]\].2aB 6High impact and low frequency exercise - e.g., running or jumping - must be recommended for healthy children and adolescents \[[@CR31], [@CR42]--[@CR46]\].1aA 7This kind of sport must also be recommended for children with low BMD \[[@CR23], [@CR47], [@CR48]\].3aC 8It is important to recommend exposure to sunlight on the hands, face and arms between six to eight minutes/day in the summer (avoiding the hottest part of the day between 10 a.m. and 3 p.m.) and 30 min/day during the coldest months of the year \[[@CR15], [@CR49], [@CR50]\].4D90%Complementary test 9Children with chronic diseases are at greater risk of vitamin D deficiency than the generalpopulation. Therefore, it would be advisable to monitor them, mostly during the end of winter \[[@CR49]--[@CR51]\].2aB 10Regarding all children and adolescents who are suspected of suffering from secondary osteoporosis, the following lab work for the initial study is recommended: blood and urine chemistry, urine screening and bone turnover markers (Table [6](#Tab6){ref-type="table"}) \[[@CR52]\].5D83% 11The role of bone turnover makers in pediatric populations with bone fragility is insufficiently defined, but they can be useful in treatment follow-up and evaluation. For this reason, they are included in the initial study of these patients \[[@CR23], [@CR52]--[@CR56]\].5D80% 12Measurements of bone turnover makers in urine are not recommended for all patients since the collection of the sample may be not correctly carried out due to the patient's age or concomitant disease \[[@CR57]\].5D90% 13Specific complementary tests detailed in Table [7](#Tab7){ref-type="table"} can be carried out for some children and adolescents depending on the suspected underlying condition \[[@CR15], [@CR23], [@CR58]\].5D90% 14Interpretation of analytical values must be done taking into consideration the factors that modify them. These factors are biological (age, sex, pubertal stage, ethnicity) and other controllable variables (circadian rhythm, diet, season of the year) \[[@CR53], [@CR55]--[@CR61]\].2bB 15Since low bone mass has been associated with increased fracture risk, DXA is the most recommended method for pediatric populations in order to assess bone health. However, it does not allow for a prediction of fracture risk \[[@CR34], [@CR48], [@CR62], [@CR63]\].2aB 16DXA of the lumbar spine and total body less head (TBLH) is the chosen method to measure BMD in pediatric populations, since they are the most accurate and reproducible areas of the skeletal system for this measurement \[[@CR6], [@CR64], [@CR65]\].2aB 17Data analyses must be carried out using pediatric software (software for adults overestimates BMD) \[[@CR66], [@CR67]\].2bB 18Vertebrae DXA measurement is recommended for children under the age of five due to its higher reproducibility and shorter time necessary for conducting this test \[[@CR5], [@CR6], [@CR64], [@CR66], [@CR67]\].2aB 19For children under the age of three, total body BMD is not recommended on a routine basis due to its lack of reproducibility in such young children; rather BMC should be used \[[@CR5], [@CR6], [@CR64]\].3aC 20Regarding children of short stature (\< p3) or with a growth retardation problem, it is recommended to adjust their results by means of a size Z-score \[[@CR6], [@CR23], [@CR64], [@CR68], [@CR69]\].2aB 21For children suffering from joint contracture or with mobility problems - e.g., with cerebral palsy - distal femur measurement can be an alternative \[[@CR68]\].2aB 22For children with suspected secondary osteoporosis, it is recommended to extend the study with a plain lateral thoracic and lumbar X-ray to assess vertebral compression fractures, particularly if they are receiving GCs \[[@CR23], [@CR70]--[@CR73]\].2bB 23In the event of low bone mass or risk factor persistence, a second plain lateral thoracic and lumbar X-ray should be taken after one year \[[@CR70], [@CR71]\] .3bC 24The minimum time interval to wait before repeating a bone density measurement is six months, a period of one year being advisable, apart from exceptional cases \[[@CR6], [@CR64], [@CR66], [@CR74], [@CR75]\].3bC 25DXA can be used to assess treatment response after six months in the event of high doses of corticosteroids, chemotherapy, or in situations of malnutrition or active treatment \[[@CR6], [@CR64], [@CR66], [@CR74]\].3bC 26In cases of children who initially present normal densitometry results, but in whom risk factor(s) persist, the periodicity of the densitometry must be individualized according to the risk factor associated and an interval of one or two years is advised until peak bone mass is reached \[[@CR6], [@CR64], [@CR66], [@CR74], [@CR75]\].5D95%Prevention 27Oral calcium supplementation could improve BMD in healthy children with a low-calcium diet. Nevertheless, increasing calcium intake by means of calcium-rich foods is preferable to supplementation \[[@CR36]--[@CR38], [@CR76]\].5D90% 28With respect to children with chronic diseases, adequate treatment of the disease is the most important step to be taken regarding osteoporosis prevention and treatment \[[@CR23], [@CR77]--[@CR79]\].2bBTreatment 29Vitamin D supplementation must be prescribed for all those patients with chronic pathologies presenting levels lower than 20 ng/mL and for those with levels between 20-30 ng/mL who present Z-score ≤ − 2 or any data showing bone fragility \[[@CR51], [@CR80], [@CR81]\].4D90% 30For children and adolescents with a low BMD or osteoporosis, calcium supplementation is recommended, particularly for those patients with a low-calcium diet, as well as supplementation of the proper amount of vitamin D~3~ in order to keep plasmatic levels of 25-hydroxyvitamin D~3~ higher than 30 ng/dL \[[@CR82], [@CR83]\].2bB-C 31The required amount of calcium and vitamin D supply needed in children with pathologies that can jeopardize intestinal absorption or modify their body's use of these nutrients is unknown. For this reason, in the event that such patients present osteoporosis or low BMD according to chronological age, it is advisable to initially prescribe the dose required to ensure a recommended daily intake of healthy children. Treatment can be modified according to plasmatic 25-hydroxyvitamin D~3,~ iPTH and calciuria levels, which must be monitored every six to twelve months \[[@CR49]--[@CR51], [@CR82], [@CR83]\].5D90% 32Treatment with BP should be administered to those pediatric patients with osteoporosis (Z-score ≤ − 2 + pathological fracture or VF regardless of Z-score) \[[@CR9], [@CR84]--[@CR88]\].1bA 33Treatment with BP can be considered for patients without osteoporosis, but a low BMD in early puberty (Tanner 2):- When active risk factors are present: patients with Z ≤ − 2. 5 SD (with a declining trajectory confirmed at least on two separate occasions with one year apart).- When patients no longer present active risk factors: patients with Z ≤ -3DS (with a declining trajectory confirmed on at least on two separate occasions with one year apart) \[[@CR9], [@CR84]--[@CR87]\].5D78% 34Intravenous BPs should be used whenever there are VF, if there is some contraindication to the use of oral BPs, or according to the patient's preferences \[[@CR88]--[@CR91]\].3aB-C 35Oral BPs can be used in the absence of contraindications and VF, or during the de-escalation phase \[[@CR9], [@CR84]--[@CR87]\].5D70% 36The BP dosage should be discontinued or progressively reduced in those patients not presenting fractures during the preceding year and having reached a Z-score higher than -2 \[[@CR9], [@CR84]--[@CR87]\].5D90%Follow-up 37A follow-up is recommended for patients at risk for osteoporosis while other risk factors persist and during treatment with calcium and/or vitamin D~3~, BPs or other osteoporosis treatments \[[@CR49], [@CR51], [@CR74]\].4D95% 38Calcium and phosphorus metabolism (serum levels of calcium, phosphorus, alkaline phosphatase, iPTH and 25-hydroxyvitamin D~3~) should be evaluated on an annual basis \[[@CR49], [@CR51]\].4D90% 39During treatment with vitamin D, it is recommended to monitor serum levels of 25-hydroxyvitamin D~3~ every 6 to 12 months, unless the dosage is changed. In such cases, patients should be monitored at 3--6 months \[[@CR49], [@CR51]\].5D88% 40During supplementation with calcium and/or vitamin D~3~, calcium/creatinine levels in urine should be monitored at least once a year. Renal ultrasounds should be conducted to rule out nephrocalcinosis in the event of calciuria increase, or when it is not possible to determine calciuria due to the patient's age or pathology \[[@CR49]--[@CR51], [@CR82], [@CR83]\].5D83% 41DXA is recommended one year after the baseline DXA, and then subsequently every 1 or 2 years depending on the trajectory observed. The minimum interval should be 6--12 months \[[@CR74]\].4D93% 42It is recommended to perform simple lateral thoracic and lumbar X-rays to assess VF every 6 months to 2 years (with 1 year being the average), according to the risk factor magnitude and the functional status of the child \[[@CR51], [@CR71], [@CR74]\].5D73% 43For pediatric patients with reduced mobility due to cerebral palsy and congenital myopathies, a spine X-ray is recommended at 6--8 years of age, or earlier in the event of back pain, and then periodically until the end of growth \[[@CR23]\].5D88% 44During treatment with intravenous BPs, assessments of laboratory parameters are recommended before each administration. For oral BPs, checks every six months are recommended \[[@CR9], [@CR84]--[@CR86], [@CR88]--[@CR92]\].5D83% 45During treatment with BPs, annual DXA is recommended \[[@CR9], [@CR84]--[@CR86], [@CR88]--[@CR92]\].5D85%Corticosteroid-induced osteoporosis 46Lateral spine x-ray is recommended in order to detect VF at the beginning of treatmentwith GCs and after one year \[[@CR70], [@CR71], [@CR93]\].2aB 47It is recommended to carry out lumbar spine or TBLH DXA within the first six months after the beginning of treatment with GCs, and then every 9 to 12 months if treatment continues \[[@CR94]\].4D85% 48It is recommended to start simultaneous treatment and/ or optimize calcium intake (500--1000 mg/day) and vitamin D 400 IU/day for those patients who are scheduled to receive systemic GCs for three months or more \[[@CR95]\].2bB 49Treatment with calcium and vitamin D must be maintained for three months after discontinuation of GCs \[[@CR95]\].5D88% 50For children and adolescents receiving GCs chronically and presenting low BMD (Z-score ≤ − 2) and pathological fractures, it is recommended to use BPs associated with calcium and vitamin D \[[@CR87], [@CR95], [@CR96]\].1bA 51Lateral spine x-rays or BMD checks with DXA are not recommended on a routine basis for those children and adolescents being treated with inhaled GCs at dosages under 800 mcg/day, unless they present other risk factors \[[@CR97]--[@CR99]\].1bA*LE* level of evidence*, GR* grade of recommendation*, LADR* Level of agreement in Delphi round*, GCs* glucocorticoids*, BMD* bone mineral density*, BMC* bone mineral content*, DXA* dual-energy x-ray absorptiometry*, iPTH* intact parathyroid hormone*, BPs* bisphosphonates*, VF* vertebral fractures

Discussion {#Sec6}
==========

When osteoporosis should be suspected {#Sec7}
-------------------------------------

Factors that contribute to osteoporosis in children and adolescents can be both genetic and lifestyle associated.

In children suffering from chronic diseases or receiving bone harmful treatments for a prolonged period of time, several factors that increase bone resorption and decrease bone formation converge and result in increased bone fragility \[[@CR100]\] \[[@CR63]\]. For this reason, bone health must be assessed during follow-up, adopting adequate preventive measures.

Table [2](#Tab2){ref-type="table"} shows some of the pathologies responsible for secondary osteoporosis. Table 2Causes of secondary osteoporosisNeuromuscular disordersCerebral palsyDuchenne muscular dystrophyRett syndromeMyopathiesDiseases resulting in long-term immobilizationHematological diseasesLeukemiasHemophiliaThalassemiaSystemic autoimmune diseasesJuvenile systemic lupus erythematosusJuvenile dermatomyositisSystemic juvenile idiopathic arthritisSystemic sclerosisLung diseasesCystic fibrosisGastrointestinal diseasesCeliac diseaseInflammatory bowel diseaseChronic liver diseaseCow's milk protein allergyRenal diseasesNephrotic SyndromeChronic renal failurePsychiatric illnessesAnorexia nervosaInfectious diseasesHIV infectionImmunodeficienciesEndocrine diseasesDelayed pubertyHypogonadismTurner syndromeKlinefelter SyndromeGrowth hormone deficiencyAcromegalyHyperthyroidismDiabetesHyperprolactinemiaCushing syndromeAdrenal insufficiencyHyperparathyroidismVitamin D metabolism disordersInborn errors of metabolismGlycogen storage diseaseGalactosemiaGaucher diseaseSkin conditionsEpidermolysis bullosaIatrogenesisSystemic glucocorticoidsCyclosporineMethotrexateHeparinAnticonvulsantsRadiation therapy

There is no universal consensus regarding when and how to assess bone health for all of the pathologies involved. However, there are some clinical guidelines for different pediatric disorders (Table [3](#Tab3){ref-type="table"}). Table 3Assessment of BMD for certain diseases or chronic treatments involved in childhood secondary osteoporosisDisease / TreatmentBMD assessmentCeliac diseaseDXA if:-no adequate dietary adherence-irregular menstruation-anemia-other risk factors for fractures \[[@CR74]\]Cerebral palsyDifficult lumbar spine X-ray interpretation in cases of severe scoliosis.Total-body or distal femur DXA (area with higher fracture risk), only if there are fragility fractures \[[@CR8]\].Duchenne muscular dystrophyBaseline DXA and annual monitoring.Lateral spine x-ray: Baseline- On GCs treatment: Repeat every 1--2 years.- Not on GCs treatment: Repeat every 2--3 years.- If back pain or ≥ 0, 5 SD decline in spine BMD Z score on serial measurements over 12-month period: Repeat.Refer to osteoporosis specialist following the first fracture \[[@CR11]\].Rett syndromeBaseline DXA, and serial controls according to individual risk \[[@CR15]\].EpilepsyConsider DXA for epileptic patients receiving anti-epileptic drugs for a prolonged period \[[@CR13]\]ThalassemiaDXA every 2 years from adolescence \[[@CR12]\]Inflammatory/ systemic diseaseConsider DXA for patients receiving high doses of GCs \[[@CR74]\].Juvenile idiopathic arthritis (JIA)\<  6 years: DXA in the presence of fragility fractures.\>  6 years: DXA if not presenting rapid remission of JIA or in need of high doses of GCs \[[@CR18]\].NeoplasmsBaseline DXA two years after completing chemotherapy with osteotoxic drugs; e.g., MTX, GCs or hematopoietic cells transplantation; or secondary effects that favor osteoporosis development (growth hormone deficiency, hypogonadism, etc.)DXA follow-up based on the results of baseline DXA and persistent risk factors \[[@CR17]\]Cystic fibrosisDXA in children ≥ age 8 if:- weight \< 90% ideal weight- FEV~1~ \< 50%- Delayed puberty- High dosis of GCs \> 90 days per yearAt 18, all of them \[[@CR101]\].Diabetes mellitusDXA if:- low BMD specific risk factors- increased daily insulin dosis- impaired renal function- fracture history \[[@CR74]\]Anorexia nervosaDXA in patients with amenorrhea for more than 6 months \[[@CR13]\].Systemic lupus erythematosusDXA evaluation in patients with prolonged systemic GCs exposure exceeding ≥0.15 mg/kg daily for ≥ 3 months. Repeat on an annual basis if Z-score ≤ − 2 \[[@CR102]\].*DXA* dual-energy x-ray absorptiometry*, BMD* bone mineral density*, GCs* glucocorticoids*, MTX* methotrexate*, FR* risk factors

BMD in patients with chronic diseases should be monitored based on the existing guidelines for each disorder. In addition, special attention must be paid to patients suffering from chronic diseases and receiving treatment that may favor the development of osteoporosis; e.g., glucocorticoids (GCs), chemotherapy or antiepileptic drugs.

How to prevent osteoporosis {#Sec8}
---------------------------

There are numerous factors that impact bone health in children. Many of these are modifiable, at least in part (Table [4](#Tab4){ref-type="table"}) \[[@CR35]\]. Table 4Risk factors of osteoporosis in childhoodModifiableNutritional• Caloric intake• Protein intake• Calcium intake• Phosphorus intake• Vitamin D• Others (vitamins K, group B, Mg, K ...)Lifestyle• Solar exposure• Physical exercise• Tobacco• AlcoholPartly modifiableHigh risk diseases• Prematurity• Pregnancy and nursing in adolescents• Intestinal malabsorption• Cystic fibrosis• Celiac disease• Inflammatory bowel disease• Food allergies• Chronic lactose intolerance• Chronic liver disease• Chronic kidney disease• Cerebral palsy• Chronic rheumatic diseases ...Hormonal• Treatment with glucocorticoids• Hyperparathyroidism• HypogonadismNon- modifiableGeneticsSexEthnicity

Nutritional factors with higher evidence of conferring a positive effect on bone health are calcium, phosphorus and vitamin D \[[@CR23]\]. Table [5](#Tab5){ref-type="table"} shows the daily nutrient requirements for a healthy child \[[@CR103]\], although children suffering from chronic diseases or under treatment with drugs that alter intestinal absorption may need higher intakes of calcium and vitamin D \[[@CR23], [@CR35], [@CR49], [@CR104]\]*.* Table 5Daily calcium and vitamin D requirements according to ageAgeCalcium (mg)Vitamin D (IU)0--6 months2004006--12 months2604001--3 years7006004--8 years10006009-18 years1300600

Calcium-rich foods are preferable to supplements for attaining optimal calcium intake, not only because they have a higher bioavailability \[[@CR23]\] and are easier to digest, but also because their consumption avoids possible secondary cardiovascular effects common in adults \[[@CR105]\] and favors positive nutritional habits from childhood \[[@CR23]\]. Thus, systematic supplementation with calcium in the absence of osteoporosis or low BMD is not recommended \[[@CR106]\]. It should only be considered for those patients with calcium-poor diets \[[@CR42]\].

Vitamin D is an important hormone for the absorption and use of calcium \[[@CR103]\]. There is some dispute regarding the optimal levels of vitamin D, although in general terms, serum levels of 25-hydroxyvitamin D~3~ ≥ 50 nmol/L (20 ng/mL) are considered normal. Those between 30-50 nmol/L (12-20 ng/mL) are regarded as insufficient, and those \< 30 nmol/L (12 ng/mL) deficient \[[@CR49]\].

In order to maintain appropriate levels, the intake of food enriched in vitamin D is important, as well as daily exposure to sunlight on the hands, face and arms for 6 to 8 min in the summer months (avoiding the hottest part of the day) and 30 min in the coldest months of the year. However, there is no exposure to ultraviolet B (UVB) rays that is safe in terms of skin cancer \[[@CR49]\]*.*

Children suffering from chronic diseases have an increased risk of vitamin D deficiency. Therefore, monitoring vitamin D serum levels would be advisable in these patients, especially in late winter \[[@CR104]\].

In addition, a large number of other nutrients play a significant role in bone metabolism, such as proteins, potassium, magnesium, copper, iron, phosphate, zinc and vitamin A, C and K \[[@CR23], [@CR104]\]. Thus, it is important to recommend a varied diet, including fruits and vegetables, to ensure an adequate intake of key nutrients in order to maintain good bone health in children and adolescents \[[@CR23], [@CR35], [@CR104]\].

Moreover, exercise and regular physical activity are considered among the most effective strategies for maximizing peak bone mass during childhood \[[@CR23], [@CR35], [@CR42], [@CR104]\]. High impact and low frequency exercise - e.g., jumping, running or resistance training - favor BMD increase in children and are more suitable than others such as swimming or biking in terms of bone health \[[@CR35], [@CR43], [@CR104]\]. Nevertheless, physical activity with excessive impact increases fracture risk \[[@CR44]\].

There are other factors such as tobacco, caffeine and alcohol consumption that are associated with decreased BMD and increased fracture risk \[[@CR35], [@CR37], [@CR38], [@CR104]\]. This is one reason, among others, to avoid their consumption in children and adolescents.

It is also essential to maintain an adequate nutritional state because both, extreme thinness and adiposity, are associated with lower BMD and increased fracture risk \[[@CR29], [@CR30], [@CR35]\].

Furthermore, the optimal control of the primary disease is the most effective way to prevent and treat secondary osteoporosis \[[@CR23], [@CR35]\].

Diagnosis {#Sec9}
---------

### Laboratory tests {#Sec10}

The diagnosis of secondary osteoporosis is usually made after the diagnosis of the underlying disease that causes it. However, in some cases, it may be the first manifestation of the underlying disease. Although most of the disorders included in the differential diagnosis can be inferred by means of a thorough medical history review and physical examination, some pathologies - e.g., phosphocalcic metabolism alterations, hypothyroidism or some types of leukemia- can be paucisymptomatic and require complementary tests for accurate diagnosis \[[@CR100]\]. For this reason, it is recommended to perform the analytical parameters listed in Table [6](#Tab6){ref-type="table"} when assessing a child with suspected or established diagnosis of secondary osteoporosis. Regarding the parameters shown in Table [7](#Tab7){ref-type="table"}, they are only justified in the event of clinical suspicion. Table 6Basic Diagnostic StudiesLaboratory testVariables to analyzeBlood count Blood chemistryCalcium, ionized calcium, phosphorus, magnesium, total proteins, creatinine, urea, glucose, 25-hydroxyvitamin D~3~, PTH, TSH, free T4  24-hour urine chemistryCalcium, phosphorus, creatinine, tubular phosphorus reabsorption, sodium Urine screeningCa/Creatinine^a^ Bone turnover makersTotal alkaline phosphatase^a^Sample from a single urination, preferably first one in the morning Table 7Analytical determinations to make based on suspicionStudies1Immunoglobulins2Anti-transglutaminase IgA antibodies3Cortisol4Prolactin5FSH, LH, testosterone6Homocysteine7Genetic studies (genes related to osteogenesis imperfecta and disorders characterized by bone fragility)

These biochemical parameters must be interpreted based on factors such as age, sex, growth rate, nutritional status and pubertal stage, among others \[[@CR52], [@CR59]\].

Bone turnover markers are certain substances released into the bloodstream during bone formation or resorption that reflect bone metabolic activity at a given time. Though numerous, amino-terminal propeptides from type 1 procollagen (P1NP) and carboxy-terminal telopeptides (CTx) should be used as reference markers to evaluate formation and resorption, respectively \[[@CR107], [@CR108]\]. These can be measured in the blood and urine \[[@CR109]\], although for children it is preferable to determine them in plasma \[[@CR53], [@CR110], [@CR111]\]. In adults, they have been shown to be useful for monitoring treatment in patients with osteoporosis \[[@CR112]\]. In children, however, such interpretation is much more complex \[[@CR54], [@CR110], [@CR113]\], although they can help in monitoring antiresorptive therapy compliance and measuring its effectiveness \[[@CR100]\].

### Imaging tests {#Sec11}

The diagnosis of childhood osteoporosis is essentially based on the presence of fragility fractures. However, a dual-energy x-ray absorptiometry (DXA) is recommended to ensure a complete assessment of bone health \[[@CR5]\].

Despite numerous limitations \[[@CR100]\], DXA is the chosen method for determining bone health in children. Lumbar spine and total-body less head are the preferred skeletal sites for performing DXA as they are the most accurate and reproducible areas in children. In addition, Z-score should be adjusted according to the height in children with a size below the 3rd percentile \[[@CR5]\].

Other techniques for assessing bone quality in pediatrics are peripheral quantitative computed tomography and ultrasound. However, although superior to DXA in certain aspects, there are insufficient studies of pediatric populations to recommend their use on a routine basis \[[@CR100]\].

Furthermore, in a patient with suspected or confirmed bone fragility, the presence of VF, which are frequently asymptomatic, should always be assessed by means of a simple lateral full spine x-ray or by DXA vertebral fracture assessment, if feasible \[[@CR39], [@CR114]\].

Treatment {#Sec12}
---------

### Calcium and vitamin D supplementation {#Sec13}

Calcium and vitamin D supplementation have not shown any clinically significant effect on BMD in studies performed in healthy children \[[@CR106]\]. In contrast, some studies have reported a favorable effect in patients with chronic diseases that favor osteoporosis such as cerebral palsy \[[@CR8]\]. On the other hand, no side effects have been reported \[[@CR8], [@CR40]\]. Thus, although there are no studies that assess the effect of supplementation on the incidence of fractures, calcium supplementation is considered advisable in children and adolescents with low BMD or osteoporosis, especially those patients with a low dietary intake.

Likewise, ensuring proper vitamin D~3~ intake is recommended in order to maintain plasmatic levels of 25-hydroxyvitamin D~3~ higher than 50 nmol/l (20 ng/dL).

Table [6](#Tab6){ref-type="table"} shows the recommended daily intake of calcium and vitamin D for healthy children \[[@CR103]\]. The optimal intake for children with disorders that may interfere with intestinal absorption or modify calcium metabolism remains unknown \[[@CR41]\]. Thus, initially, supplementation should be prescribed with respect to these recommendations and subsequently be modified according to plasmatic 25-hydroxyvitamin D~3,~ intact paratohormone (iPTH) and calciuria, which must be monitored every 6--12 months.

### Bisphosphonates {#Sec14}

BPs are synthetic analogs of pyrophosphate that inhibit bone resorption. They selectively concentrate and increase BMD in high remodeling rates skeleton areas \[[@CR115]\]. They are hydrophilic drugs with low intestinal absorption (\< 1%) and high distribution volumes that are excreted in urine. Thus, dosages must be adjusted according to glomerular filtrate. Moreover, they are characterized by a very slow elimination from bone tissue, and remain in the body for years after treatment \[[@CR115]\].

Knowledge on the mid- and long-term safety of these drugs is constantly increasing \[[@CR100]\]. Thus, some authors recommend their use as long as osteoporotic criteria are met, particularly in those patients with long bones and VF and who exhibit poor potential for spontaneous recovery (age at puberty, risk factor persistence, etc.) \[[@CR116]\].

To date, BPs have only been prescribed as a secondary prevention measure. In other words, once the first fracture occurs. Their use is intended to prevent the appearance of new fragility fractures. It is currently known that they confer a positive effect on BMD \[[@CR9], [@CR84]--[@CR87]\], and there is increasing knowledge regarding their long-term safety \[[@CR100]\]. On the other hand, if the peak bone mass reached at the end of the growth stage is not optimal, osteoporosis is more likely to develop during the later stages of life \[[@CR3]\]. On the basis of the above data, our working group recommends that clinicians consider treatment with BPs for those patients without osteoporosis, but low BMD in early puberty, with low Z-scores and decreasing trajectories.

In any case, BPs are used off label in childhood osteoporosis, so informed consent must be obtained when they are prescribed.

Second and third generation BPs are the most commonly used BPs in children. Some of them are intravenously administered and others orally \[[@CR100]\]. Oral BPs are widely used in adulthood osteoporosis, and some studies have demonstrated that they increase BMD and decrease fracture risk in patients with Osteogenesis Imperfecta. Nevertheless, in contrast to intravenous BPs, they lack sufficient potency to induce remodeling after VF \[[@CR117]\] and are contraindicated in patients with esophagitis risk factor; e.g., gastroesophageal reflux or hiatal hernia. Intravenous BPs are preferred for pediatric osteoporosis, and oral BPs are only used for patients with mild forms of osteoporosis, without VF, when intravenous administration is contraindicated for any reason, or during the treatment maintenance phase \[[@CR100]\].

Table [8](#Tab8){ref-type="table"} shows doses and dosing intervals for the most commonly used BPs in pediatrics \[[@CR100]\]. Table 8Doses and dosing intervals for the most commonly used BPs in pediatricsDrugAdministrationDosePamidronate(2nd generation)Intravenous (dilute in 100-250 ml physiological saline solution, in 3--4 hours)\<  1 year: 0. 5 mg/kg every 2 months1--2 years: 0. 25-0. 5 mg/kg/day 3 days every 3 months2--3 years: 0.375--0.75 mg/kg/day 3 days every 3 months\>  3 years: 0. 5--1 mg/kg/day 3 days every 4 monthsMaximum dose: 60 mg/dose and 11. 5 mg/kg/yearNeridronate(3rd generation)Intravenous (dilute in 200--250 ml physiological saline solution, in 3 hours)1--2 mg/kg/day every 3--4 monthsZolendronate(3rd generation)Intravenous (dilute in 50 ml physiological saline solution, in 30-45 min)0.0125--0.05 mg/kg every 6--12 months (maximum dose 4 mg)Alendronate(2nd generation)Oral1--2 mg/kg/week\<  40 kg: 5 mg/day or 35 mg/week\>  40 kg: 10 mg/day or 70 mg/weekMaximum dose: 70 mg/weekRisendronate(3rd generation)Oral15 mg/week (\<  40 kg); 30 mg/week (\> 40 kg)Maximum dose: 30 mg/week

The optimal treatment duration is not clearly defined and is currently based on expert recommendations \[[@CR116]\]. We propose discontinuing or progressively decreasing BPs dosing for those patients who have not presented fractures during the preceding year and who have attained a Z-score higher than -2.

Follow-up {#Sec15}
---------

The aim of follow-up in patients with osteoporosis risk factors is to identify those candidates who need to start or maintain specific treatments. For such patients and those with an established osteoporosis diagnosis, follow-up should be continued as long as risk factors persist or while treatment is maintained with calcium and/or vitamin D~3~, BPs or other medications for osteoporosis \[[@CR49], [@CR51], [@CR74]\].

Clinical, radiological and analytical parameters should be monitored. Assessing the number of fragility fractures and pain episodes is important. In terms of densitometry, variations in Z-scores are relevant. The optimal frequency for DXA performance is insufficiently defined \[[@CR74]\]. Our recommendation is to repeat DXA after one year, and then every 1--2 year thereafter according to the patient's trajectory, with a minimum interval between checks of 6--12 months.

It is also crucial to perform a radiological assessment of VF, since they are frequently asymptomatic and can appear even in patients with Z-scores higher than -2 \[[@CR23]\]. Moreover, their evolution can lead to changes in treatment \[[@CR116]\]. There are no studies that have definitively determined how often VF should be monitored, although some authors propose lateral spine x-rays on an annual or biannual basis \[[@CR23]\]. We propose their frequency be individualized according to the patient's risk factors, with a minimum period of 6 months and a maximum period of 2 years.

In addition, no studies or guidelines have established the optimal periodicity for assessing phosphocalcic metabolism. Our recommendation is to make an analytical determination on an annual basis.

In regard to patients receiving calcium and vitamin D supplementation, since the optimal intake for children and adolescents suffering from chronic diseases is unknown \[[@CR41]\], doses should be modified according to calciuria and plasmatic levels of 25-hydroxyvitamin D~3~ and iPTH. The optimal frequency for monitoring these parameters is unknown \[[@CR49]\], although some authors advocate that determinations should be made every 3--12 months \[[@CR49], [@CR51]\]. Our working group recommends that levels of 25-hydroxyvitamin D~3~ should be determined every 6--12 months, or after 3--6 months after a dose change. Furthermore, an annual determination of calciuria is recommended. A renal ultrasound should be conducted to rule out nephrocalcinosis in the event of calciuria increase, or when urine collection is not possible.

Regarding children being treated with BPs, there are no studies that have determined an optimal frequency for analytical checks. Our group recommends monitorization prior to each infusion for patients receiving intravenous BPs, and every 6 months for patients taking BPs orally.

### Corticosteroid-induced osteoporosis {#Sec16}

GCs are widely used with a proven effectiveness in numerous pediatric diseases. However, they carry multiple side effects, and are associated with decreased BMD and bone fragility fractures \[[@CR118]\].

Patients treated with systemic GCs lose bone mass more markedly during the first 3--6 months of treatment, mainly trabecular bone \[[@CR118]\]. This loss depends on the dose and treatment duration \[[@CR119], [@CR120]\]. Although lower doses are less harmful than higher doses, there appears to be no unequivocally safe dose since fracture risk have been reported to persist with prednisone (or equivalent) doses of 2. 5 a 7. 5 mg/ day \[[@CR118]\].

Thus, as in other patients with osteoporosis risk factors, monitoring BMD and VF occurrence is advisable. In the absence of clear data on the optimal time for a DXA in this group, we recommend performing a DXA during the first 6 months of treatment, and repeating it every 9-12 months if treatment continues.

Regarding VF screening, some studies reported an incidence rate of around 10% during the first year, with nearly 50% of such cases being asymptomatic \[[@CR70], [@CR71]\]. For this reason, it is advisable to assess these patients using imaging technique at the beginning of treatment, and thereafter annually while GCs are maintained.

The Spanish Rheumatology Society Consensus \[[@CR121]\] holds that the prevention of GIOP must begin as early as possible for all patients receiving doses higher than 5 mg/day of prednisone (or equivalent) for more than three months. Preventive actions include prescribing the lowest possible dose of GCs to control the underlying disease, as well as encouraging physical exercise, avoiding toxic products, such as tobacco and alcohol, and ensuring a balanced diet with the required intake of calcium and vitamin D \[[@CR121]\]. In fact, a recent systemic review concluded that calcium and vitamin D supplementation should be started with the same dose recommended for healthy children in all children on GCs, particularly when treatment is expected to last more than 3 months, as a preventive action against GIOP development \[[@CR95]\]. In addition, our group recommends maintaining this supplementation for three months after discontinuation of GCs treatment since its effect on bone continues even after treatment has been halted. Nevertheless, no studies have determined an optimal period of supplementation. This same review recommends the use of BPs for preventive purposes \[[@CR95]\], despite the lack of any comprehensive data. Our own working group does not consider its systematic use in the absence of fragility fractures. Nevertheless, its effectiveness is proven when GIOP has been established; i.e., when pathological fractures are clearly evident \[[@CR87], [@CR95], [@CR96]\].

Most studies suggest that an inhaled GCs dose lower than the equivalent of 800 mcg/day of budesonide has only a minimum effect on fracture risk, while higher doses are associated with an accelerated decrease in BMD and a higher risk of fractures. In these patients, although non-pharmacological preventive actions are justified \[[@CR97], [@CR98], [@CR122]\], it is not advisable to routinely carry out such procedures as lateral spine x-rays or DXAs, unless these patients have other risk factors \[[@CR97]--[@CR99]\]. Furthermore, the role of calcium and vitamin D supplementation in patients prescribed inhaled GCs has not yet been established, although some groups recommend supplementation for higher risk populations \[[@CR93]\].

Conclusion {#Sec17}
==========

In summary, we present herein guidelines for the prevention, diagnosis and treatment of secondary childhood osteoporosis based on the available evidence and expert clinical experience. We believe it can serve as a useful tool that will contribute to the standardization of clinical practice for this pathology. Prophylactic measures, early diagnosis and a proper therapeutic approach are essential to improving bone health, not only in children and adolescents, but also in the adults they will become in the future.

*BMC*

:   Body mass content

*BMD*

:   Body mass density

BPs

:   Bisphosphonates

CEBM

:   Centre for Evidence-based Medicine

CTx

:   Carboxy-terminal telopeptides

DXA

:   Dual-energy x-ray absorptiometry

GCs

:   Glucocorticoids

GIOP

:   Glucocorticoid-induced osteoporosis

iPTH

:   Intact paratohormone

P1NP

:   Amino-terminal propeptides from type 1 procollagen

SERPE

:   Pediatric Rheumathology Spanish Society

UVB

:   Ultraviolet B

VF

:   Vertebral fractures
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